What Starling Oncology, Inc. does.

Formed in 2007, the business of what is now The Oncology Institute, Inc. ("TOI", the "Company", "we", or "our) and its affiliated professional corporations was created initially as a collection of community oncology practices in southern California, and has evolved to be a national leader in the pursuit of reducing the ever-rising cost of oncology care, while embracing clinical best practices, state-of-the-art technology, and compassionate treatment of patients.

While we continue our original purpose of seeing our patients on a fee-for-service basis for their oncology, hematology, specialty infusion, oral pharmacy needs, as well as enrolling patients in clinical trials, where appropriate, TOI's true mission lies in our differentiated ability to partner with managed care providers and other risk-bearing entities to transfer the risk and patient coordination responsibility of treating cancer in the subset of the population that is experiencing an oncology treatment episode. To do this, we utilize a combination of gain/loss sharing, capitation, and full delegation contracts at the population-level, which allow TOI to control the treatment of oncology patients in an outpatient setting, across both medical oncology (traditional IV-based infusion therapy) and radiation oncology (radiation therapy provided by linear accelerator equipment).

Revenue and profit, by fiscal year.

More on STLN.

• Starling Oncology, Inc. summary
• Starling Oncology, Inc. financial statements
• Starling Oncology, Inc. key metrics
• Starling Oncology, Inc. health scores and style box
• Starling Oncology, Inc. earnings
• Starling Oncology, Inc. dividends
• Starling Oncology, Inc. valuation
• Starling Oncology, Inc. ownership and insiders
• Starling Oncology, Inc. peers

Figures from Starling Oncology, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.